AdaptHealth (AHCO) Earnings Date & Reports

Key Takeaways

• AdaptHealth reported third quarter 2026 net revenue from continuing operations of $745.6 million, up 10.9% year over year and above the roughly $726 million consensus estimate.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $141.9 million, ahead of the approximately $130 million consensus expectation.
• On a GAAP (generally accepted accounting principles) basis, the company posted a net loss attributable to AdaptHealth of $168.2 million, driven largely by a $184.8 million non-cash goodwill impairment charge.
• GAAP earnings per share (EPS) of -$1.13 came in well below the consensus estimate of roughly -$0.06, reflecting the one-time impairment.
• Management raised its full-year revenue guidance midpoint to approximately $2.89 billion, and its adjusted EBITDA outlook landed above analyst expectations.
• Shares jumped roughly 9.6% to around $6.48 immediately following the release, signaling a favorable reaction to the operating beat despite the headline loss.
• For more context on AdaptHealth, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover additional trading ideas and market opportunities, explore Trending AI Robots.

Earnings Context and Why It Matters

AdaptHealth Corp. is a national provider of patient-centered, healthcare-at-home solutions, spanning home medical equipment (HME), supplies, and related services across sleep, respiratory, and wellness categories. The third quarter of 2026 arrived at a pivotal moment in the company's transformation, as management works through the largest patient transition in the industry's history while executing a portfolio simplification that includes the pending sale of its Diabetes Health business. Investors are watching closely to see whether the company's largest capitated contract can turn from a margin drag into a source of profitable growth, and whether cost discipline can offset integration expenses. This report matters because it offers a clearer read on organic demand, profitability trends, and the credibility of full-year guidance during a period of significant restructuring.

Reported Results

AdaptHealth reported third quarter 2026 net revenue from continuing operations of $745.6 million, an increase of 10.9% versus the prior-year quarter, with organic growth of 12.8%. Revenue came in about $15.6 million above the midpoint of the company's own guidance and exceeded consensus estimates of roughly $726 million. On a reported basis, Sleep Health revenue rose 11% to $393.9 million, Respiratory Health revenue grew 7.8% to $190.8 million, and Wellness at Home revenue increased 14.5% to $161 million. Total capitated revenue reached $110.3 million, or about 15% of continuing operations revenue.

Adjusted EBITDA was $141.9 million, compared with $146.1 million in the prior-year quarter, representing a margin of 19.0% versus 21.7% a year ago. The result beat consensus estimates of approximately $130 million. On a GAAP basis, the company reported a net loss attributable to AdaptHealth of $168.2 million, driven primarily by a $184.8 million non-cash goodwill impairment charge tied to the decline in its equity market capitalization. This produced a GAAP EPS loss of -$1.13, below consensus expectations, though the impairment and a related $12 million gain on the contribution of its e-commerce business were excluded from adjusted EBITDA.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to streamline your research and surface actionable candidates across the market, the AI Screener offers a structured, data-driven way to begin that process.

Market Reaction and Investor Sentiment

Investors responded favorably to the operating results despite the headline GAAP loss. Shares rose roughly 9.6% to around $6.48 immediately after the release, reflecting a focus on the revenue and adjusted EBITDA beats, the improving margin trajectory of the company's largest capitated contract, and the lifted full-year revenue outlook. The goodwill impairment, while substantial on a GAAP basis, was non-cash and tied to the company's reduced equity market capitalization, which appeared to limit its impact on sentiment. The market's reaction suggests that investors are placing greater weight on stabilization in the core business and the progress toward a more focused portfolio than on the one-time accounting charge.

Forward Outlook and Key Factors to Monitor

Management raised its full-year revenue guidance midpoint to approximately $2.89 billion, while its adjusted EBITDA outlook for the year came in above analyst consensus. This indicates growing confidence in the core business as the company exits a period of heavy transition work.

A central item to monitor is the pending sale of the Diabetes Health business. Closing that transaction would complete a multi-year effort to concentrate the portfolio around Sleep Health, Respiratory Health, and Wellness at Home, and it could reshape both reported revenue and adjusted EBITDA comparisons in future quarters.

Investors should also track the performance of the largest capitated contract, which improved from a negative margin in the second quarter to roughly 10% in the third quarter and was trending near 14% exiting the period. Continued margin expansion there, combined with labor and operating-expense discipline, will be key to sustaining adjusted EBITDA growth.

Finally, watch balance-sheet developments. The company ended the quarter with net debt of about $1.85 billion and a consolidated total leverage ratio of approximately 3.05 times. Any further debt reduction, along with cost trends and demand signals in sleep and respiratory resupply, will help define whether the momentum management describes carries into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations